Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma
Clinical trial NCT02366195 · COMPLETED
Trial details
- NCT number
- NCT02366195
- Sponsor
- Amgen
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-04-07
- Primary completion
- 2017-06-26
- Enrollment
- 112
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.